实体瘤中P-糖蛋白逆转的临床试验。 - Suppr

Suppr

超能文献

Clinical trials of P-glycoprotein reversal in solid tumours.

作者信息

Ferry D R, Traunecker H, Kerr D J

机构信息

Institute of Cancer Studies, University of Birmingham, U.K.

出版信息

Eur J Cancer. 1996 Jun;32A(6):1070-81. doi: 10.1016/0959-8049(96)00091-3.

DOI:10.1016/0959-8049(96)00091-3

PMID:8763349

Abstract

摘要

相似文献

Clinical trials of P-glycoprotein reversal in solid tumours.实体瘤中P-糖蛋白逆转的临床试验。

Eur J Cancer. 1996 Jun;32A(6):1070-81. doi: 10.1016/0959-8049(96)00091-3.

Clinical reversal of multidrug resistance.多药耐药性的临床逆转

Cancer Treat Res. 1994;73:149-65. doi: 10.1007/978-1-4615-2632-2_8.

In vitro efficacy of known P-glycoprotein modulators compared to droloxifene E and Z: studies on a human T-cell leukemia cell line and their resistant variants.与屈洛昔芬E和Z相比，已知P-糖蛋白调节剂的体外疗效：对人T细胞白血病细胞系及其耐药变体的研究。

Leuk Lymphoma. 1998 Nov;31(5-6):589-97. doi: 10.3109/10428199809057619.

Reversal of multidrug resistance in acute myeloid leukaemia and other haematological malignancies.急性髓系白血病及其他血液系统恶性肿瘤中多药耐药的逆转

Eur J Cancer. 1996 Jun;32A(6):1062-9. doi: 10.1016/0959-8049(96)00054-8.

Diagnosis and reversal of multidrug resistance in paediatric cancers.儿童癌症中多药耐药的诊断与逆转

Eur J Cancer. 1996 Jun;32A(6):1051-61. doi: 10.1016/0959-8049(96)00085-8.

Cyclosporin A and doxorubicin-ifosfamide in resistant solid tumours: a phase I and an immunological study.环孢素A与阿霉素-异环磷酰胺用于耐药实体瘤：一项I期研究及免疫学研究

Br J Cancer. 1995 Nov;72(5):1294-9. doi: 10.1038/bjc.1995.503.

Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein.LY335979的药理学特性：一种有效的环丙基二苯并环庚烷类P-糖蛋白调节剂。

Adv Enzyme Regul. 1997;37:335-47. doi: 10.1016/s0065-2571(96)00021-0.

Pharmacological considerations in the modulation of multidrug resistance.多药耐药性调控中的药理学考量

Eur J Cancer. 1996 Jun;32A(6):1082-8. doi: 10.1016/0959-8049(96)00111-6.

Synergistic effects of verapamil and anti-mdr1 ribozyme on reversion of multidrug resistance in the P-glycoprotein-positive K562 cell line.

Leukemia. 2001 Apr;15(4):696-7. doi: 10.1038/sj.leu.2402072.

Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers.通过药理学化学增敏剂对P-糖蛋白介导的多药耐药性进行实验性逆转。

Eur J Cancer. 1996 Jun;32A(6):991-1001. doi: 10.1016/0959-8049(96)00047-0.

引用本文的文献

Elacridar Inhibits BCRP Protein Activity in 2D and 3D Cell Culture Models of Ovarian Cancer and Re-Sensitizes Cells to Cytotoxic Drugs.艾拉司群在卵巢癌的二维和三维细胞培养模型中抑制乳腺癌耐药蛋白（BCRP）的蛋白活性，并使细胞对细胞毒性药物重新敏感。

Int J Mol Sci. 2025 Jun 17;26(12):5800. doi: 10.3390/ijms26125800.

The Role of Elacridar, a P-gp Inhibitor, in the Re-Sensitization of PAC-Resistant Ovarian Cancer Cell Lines to Cytotoxic Drugs in 2D and 3D Cell Culture Models.P-糖蛋白抑制剂艾拉司群在二维和三维细胞培养模型中使耐紫杉醇卵巢癌细胞系对细胞毒性药物重新致敏中的作用

Int J Mol Sci. 2025 Jan 28;26(3):1124. doi: 10.3390/ijms26031124.

Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF/c-MET signaling.解析转移性结直肠癌的治疗耐药性：药物转运、表皮生长因子受体（EGFR）突变及肝细胞生长因子/间质上皮转化因子（HGF/c-MET）信号传导的作用

Front Pharmacol. 2024 Jan 10;14:1340401. doi: 10.3389/fphar.2023.1340401. eCollection 2023.

α-Acid Glycoprotein-Decorated Hyaluronic Acid Nanoparticles for Suppressing Metastasis and Overcoming Drug Resistance Breast Cancer.用于抑制乳腺癌转移和克服耐药性的α-酸性糖蛋白修饰的透明质酸纳米颗粒

Biomedicines. 2022 Feb 9;10(2):414. doi: 10.3390/biomedicines10020414.

Anlotinib Reverses Multidrug Resistance (MDR) in Osteosarcoma by Inhibiting P-Glycoprotein (PGP1) Function In Vitro and In Vivo.安罗替尼通过在体外和体内抑制P-糖蛋白（PGP1）功能逆转骨肉瘤的多药耐药性（MDR）。

Front Pharmacol. 2022 Jan 17;12:798837. doi: 10.3389/fphar.2021.798837. eCollection 2021.

The roles of the human ATP-binding cassette transporters P-glycoprotein and ABCG2 in multidrug resistance in cancer and at endogenous sites: future opportunities for structure-based drug design of inhibitors.人类ATP结合盒转运蛋白P-糖蛋白和ABCG2在癌症及内源性位点多药耐药中的作用：基于结构的抑制剂药物设计的未来机遇

Cancer Drug Resist. 2021;4(4):784-804. doi: 10.20517/cdr.2021.19. Epub 2021 Aug 4.

Role of ABCB1 in mediating chemoresistance of triple-negative breast cancers.ABCB1 在介导三阴性乳腺癌化疗耐药中的作用。

Biosci Rep. 2021 Feb 26;41(2). doi: 10.1042/BSR20204092.

Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics.美国食品药品监督管理局（FDA）批准的具有P-糖蛋白抑制活性的药物用于潜在癌症治疗的临床前景

Front Oncol. 2020 Nov 16;10:561936. doi: 10.3389/fonc.2020.561936. eCollection 2020.

ABC Transporters at the Blood-Brain Interfaces, Their Study Models, and Drug Delivery Implications in Gliomas.血脑界面的ABC转运蛋白、其研究模型及在胶质瘤中的药物递送意义

Pharmaceutics. 2019 Dec 23;12(1):20. doi: 10.3390/pharmaceutics12010020.

Piperlongumine Inhibits Akt Phosphorylation to Reverse Resistance to Cisplatin in Human Non-Small Cell Lung Cancer Cells ROS Regulation.胡椒碱通过ROS调节抑制Akt磷酸化以逆转人非小细胞肺癌细胞对顺铂的耐药性

Front Pharmacol. 2019 Oct 11;10:1178. doi: 10.3389/fphar.2019.01178. eCollection 2019.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验